Venatorx Pharmaceuticals
Pennsylvania
United States
About Venatorx Pharmaceuticals
Venatorx Pharmaceuticals is a private pharmaceutical company focused on antibiotics and antivirals.
65 articles about Venatorx Pharmaceuticals
-
Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.
-
Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs
12/2/2021
Venatorx Pharmaceuticals today announced that Scott McConnell, Pharm.D. has joined the Company as Vice President, Medical Affairs.
-
Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen
11/1/2021
Venatorx Pharmaceuticals announced today that it has entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”)
-
Less private investment and innovation in the development of new antibiotics are impeding efforts to combat drug-resistant infections.
-
Venatorx Pharmaceuticals to Present Data at IDWeek 2021
9/27/2021
Venatorx Pharmaceuticals today announced that the Company, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.
-
Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam
8/17/2021
Venatorx Pharmaceuticals today announced a comprehensive update about cefepime-taniborbactam, the Company’s intravenous beta-lactam / beta-lactamase inhibitor (BL/BLI)
-
Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145
7/28/2021
Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial (ClinicalTrials.gov – NCT04243863) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.
-
Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science
6/29/2021
Venatorx Pharmaceuticals today announced that Mary Beth Dorr, Ph.D. has joined the Company as Vice President, Clinical Science.
-
Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection
6/28/2021
Venatorx Pharmaceuticals today announced that the first patient was dosed in a Phase 1 clinical trial evaluating VNRX-9945, a highly potent, broadly active viral replication inhibitor for the treatment of chronic hepatitis B virus (HBV) infection.
-
Venatorx Pharmaceuticals to Present Preclinical Profile of its Hepatitis B Virus Clinical Candidate at the International Liver Congress 2021
6/21/2021
Venatorx Pharmaceuticals today announced that it will present at the International Liver CongressTM (ILC), the European Association for the Study of the Liver (EASL) annual meeting, which is scheduled to take place virtually June 23-26, 2021.
-
Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate
3/10/2021
VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021
-
Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.
-
Venatorx Pharmaceuticals Names New Head of Regulatory Affairs
1/28/2021
Chitrananda Abeygunawardana, Ph.D. will lead the development and execution of Venatorx’s global regulatory strategy for its clinical and pre-clinical anti-infectives programs for Venatorx Pharmaceuticals
-
Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC
11/24/2020
Venatorx Pharmaceuticals today announced that Robert Waltermire, Ph.D. has joined the Company as Senior Vice President, Chemistry, Manufacturing and Controls (“CMC”).
-
Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020
10/21/2020
Venatorx Pharmaceuticals today announced that it has two data presentations at IDWeek 2020, which is taking place virtually, starting today through October 25, 2020. The details of the presentations are as follows: Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-Beta-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in
-
BioSpace Movers & Shakers, Sept. 18
9/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Venatorx Pharmaceuticals Names William Sargent Senior Vice President, Commercial Strategy
9/17/2020
Venatorx Pharmaceuticals today announced that Will Sargent has joined the Company as Senior Vice President, Commercial Strategy. With over 25 years of biopharmaceutical industry experience, including multiple product and line extension launches, Mr. Sargent will be responsible for designing and executing Venatorx’s commercial strategy across its portfolio of clinical and preclinical antibacterial and antiviral programs.
-
Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen
7/27/2020
Venatorx Pharmaceuticals announced that it has been awarded a contract by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services to advance a novel series of Penicillin Binding Protein Inhibitors targeting multi-drug resistant Acinetobacter baumannii through Phase 1 clinical testing.
-
Venatorx Pharmaceuticals Named ‘Best Places to Work’ Third Year in a Row
6/30/2020
Venatorx Pharmaceuticals announced that it was named one of the “2020 Best Places to Work” in the medium-sized company category in the Greater Philadelphia area by the Philadelphia Business Journal.
-
Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections With Limited Treatment Options
4/29/2020
Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam.